Indonesia
- Capital: Jakarta
- Economy: 17th largest in the world, nominal GDP US$845 billion, 2011
- Health Expenditure: 1.9% of GDP, 2011
- Population: 237 million, 2011
- Average Life Span: 71, 2011
- Languages: Bahasa Indonesian
- Adult Literacy Rate: 92% 2011
Health Trends
- The Indonesian pharmaceutical market was estimated at U.S. $2.7 billion in 2007 and is expected to increase to U.S. $4.2 billion by 2012.
- Access to health care is not developed, hence the availability of treatment naïve patients or undiagnosed cases.
- Tertiary and teaching hospitals are predominantly used for clinical trials.
- According to WHO, Cancer mortality is reported the highest across the South East Asia region with a figure of 6.6 percent
- Leading causes of death: Ischemia, Hypertension, Cerebrovascular diseases, LRTI, COPD, DM, TB, Road Traffic Accidents and Diarrheal diseases.
Clinical Trial Landscape
- Large patient population base.
- Submission to Local EC and HA completed sequentially.
- For global trials requiring the shipping of biological samples to a central laboratory outside of Indonesia, the Materials Transfer Agreements needs to undergo MOHR (Litbangkes – Health Research and Development of Ministry of Health) review and approval.
- Not all physicians are well trained on ICH-GCP, hence selection of interested and experienced investigators are key to success of clinical trials.
- Indonesian investigators require more CRA support compared to other countries. Culturally, face-to-face meetings are usually preferred by Investigators with CRAs.
ICON in Indonesia |
Add to Comparison Tool |
- Presence in Indonesia since 2007
Services Offered
- Clinical trial application to ethics committees and health authority
- Study set up activities
- Clinical Monitoring
- Medical & Safety Services